Deficiency of interleukin-36 (IL-36) receptor antagonist (DITRA) is an autoimmune inflammatory disorder that manifests with generalized pustular psoriasis (GPP), fever, leukocytosis, and elevated C-reactive protein (CRP) levels.
DITRA is caused by loss of function mutations in the IL36RN gene (codes for the IL-36 receptor antagonist), which leads to loss of inhibition of the IL-36 receptor resulting in overexpression of NFkB, MAPK, and proinflammatory interleukins, such as interleukin-8 (IL-8), which recruits neutrophils to the skin. Often, a homozygous mutation is present, indicating an autosomal recessive inheritance pattern; however, compound heterozygous mutations have also been documented.
While the age of onset is often in infancy or childhood, onset in adolescence and adulthood has been reported. DITRA is marked by repeated, sudden-onset flares of pustular psoriasis that occur at variable intervals. Viral or bacterial infections, retinoid withdrawal, menstruation, and pregnancy have been documented as triggers for these flares.
DITRA can be a life-threatening illness and has a reported 4%-7% mortality rate without treatment.
Deficiency of interleukin-36 receptor antagonist
Alerts and Notices
Important News & Links
Synopsis
Codes
ICD10CM:
M04.8 – Other autoinflammatory syndromes
SNOMEDCT:
784339002 – Deficiency of interleukin 36 receptor antagonist
M04.8 – Other autoinflammatory syndromes
SNOMEDCT:
784339002 – Deficiency of interleukin 36 receptor antagonist
Look For
Subscription Required
Diagnostic Pearls
Subscription Required
Differential Diagnosis & Pitfalls
To perform a comparison, select diagnoses from the classic differential
Subscription Required
Best Tests
Subscription Required
Management Pearls
Subscription Required
Therapy
Subscription Required
References
Subscription Required
Last Reviewed:09/10/2021
Last Updated:03/05/2023
Last Updated:03/05/2023
Deficiency of interleukin-36 receptor antagonist